Sign up Australia
Proactive Investors - Run By Investors For Investors

Probiotec Limited provides revenue guidance on new business

Probiotec Limited provides revenue guidance on new business

Contract manufacturer Probiotec Limited (ASX:PBP) could add $10 million of revenue on an annualised basis from agreements struck with new and existing contract manufacturing customers for additional products.

This new business continues the upward trend and is expected to come on line progressively over the 2017 financial year, toward the second half.

Profit margins are said to be consistent with the company’s existing contract manufacturing business.

Probiotec is a brand owner, manufacturer from four facilities in Australia and also a distributor of a range of prescription and over-the-counter (OTC) pharmaceuticals, complementary medicines and specialty ingredients.

It recently completed for the sale of the ADP Protein Plant in South Australia with Beston Pure Dairies Pty Ltd for $7.0 million, which will be used to reduce debt levels.

The group’s net profit after tax for the half year ended 31 December 2015, from continuing activities attributable to members for the half year was $0.3 million compared to a loss of $1.0 million.

Total interest bearing liabilities, net of cash, as at 31 December 2015 was $9.8 million, a decrease of $5.2 million from $15.0 million as at 30 June 2015.

 

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

 

 



Register here to be notified of future PBP Company articles
View full PBP profile

PROBIOTEC LIMITED Timeline

Related Articles

blood_56ceb82789b61.jpg
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
1-SG02055.jpg
March 23 2016
e-Therapeutics is now targeting partners to accelerate the development of its drug discovery engine and commercialise compounds.
Drugs
February 07 2017
The hybrid pharma services and drug development group has hit some key milestones over this year as trial results are eyed.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.